Frontiers in Pharmacology (May 2022)
Corrigendum: Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers
- Yingzi Cui,
- Dongyang Cui,
- Dongyang Cui,
- Xinran Ren,
- Xinran Ren,
- Xuesong Chen,
- Guangwen Liu,
- Zhengzhi Liu,
- Yanli Wang,
- Xinyao Qu,
- Yicheng Zhao,
- Haimiao Yang
Affiliations
- Yingzi Cui
- Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China
- Dongyang Cui
- Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, China
- Dongyang Cui
- Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, China
- Xinran Ren
- School of Pharmacy, Jilin University, Jilin, China
- Xinran Ren
- Clinical Medical College, Changchun University of Chinese Medicine, Jilin, China
- Xuesong Chen
- Jilin Province Honesty Medical Technology Consulting Co., Ltd., Jilin, China
- Guangwen Liu
- Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China
- Zhengzhi Liu
- Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China
- Yanli Wang
- Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China
- Xinyao Qu
- Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China
- Yicheng Zhao
- Clinical Medical College, Changchun University of Chinese Medicine, Jilin, China
- Haimiao Yang
- Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China
- DOI
- https://doi.org/10.3389/fphar.2022.907413
- Journal volume & issue
-
Vol. 13
Abstract
No abstracts available.Keywords
